SHIRE – PANMURE GORDON’S SAVVAS NEOPHYTOU’S PROFESSIONAL VIEWS

PANMURE GORDON’S SAVVAS NEOPHYTOU’S VIEWS

SHIRE – It’s big share price move (11% increase), more than Kraft’s revised offer for Cadbury but ultimately it’s designed to increase pressure on Shire’s management to engage, with a view to settling on a recommended offer, which we would imagine will be greater than £51.15 but not higher than £55.

Unless AbbVie decides to go hostile, which is a distinct possibility, because Shire does not have the same level of support as Astra Zeneca did. One issue focuses the mind; this transaction brings Shire back to a UK domicile, which should boost the tax revenues for the UK and investment in R&D as a whole, which politicians will embrace in my view.

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: